Allogeneic stem cell therapy - Athersys

Drug Profile

Allogeneic stem cell therapy - Athersys

Alternative Names: AMI MultiStem; HLCM 051; MultiStem; PF-05285401; PF-5285401

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Athersys
  • Developer Athersys; Case Western Reserve University; Healios; MiSOT; University of Texas Health Science Center at Houston
  • Class Antiparkinsonians; Cardiovascular therapies; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I; Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Stroke
  • Phase II Myocardial infarction; Respiratory distress syndrome
  • No development reported Brain injuries; Diabetes mellitus; Graft-versus-host disease; Heart failure; Mucopolysaccharidosis I; Multiple sclerosis; Parkinson's disease; Peripheral vascular disorders; Spinal cord injuries; Transplant rejection
  • Discontinued Ulcerative colitis

Most Recent Events

  • 15 Nov 2017 Phase-II/III clinical trials in Stroke in Japan (IV) (NCT02961504)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Graft-versus-host-disease(Prevention) in European Union (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Graft-versus-host-disease(Prevention) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top